Media

The Nocturia Patient - David Sussman

Details
(Length of Conversation: 6 min) Alan Wein and David Sussman discuss the nocturia patient. David Sussman talks about the types of patients he sees suffering from overactive bladder. Despite OAB and BPH treatments many patients do not see improvement in the nocturia symptoms and up until now there has not been an FDA approved medical treatment. The field has been searching for years for something to...

Active Surveillance: Who is the Right Patient? - Matt Cooperberg

Details
Matthew Cooperberg and Charles Ryan discuss active surveillance in the low risk and low volume disease setting. The topics they highlight include defining the appropriate patient for active surveillance in 2018 and reaching a global consensus, how much age factors into active surveillance, how biomarkers and imaging are driving research and decision making in the active surveillance setting and wh...

Identifying, Assessing, and Treating the Nocturia Patient - Peter Sand

Details
(Length of Discussion: 7 min) Roger Dmochowski, MD and Peter Sand, MD discusses the standard nocturia patient, how to identify, assess, and treat them, behavioral and non pharmacological treatment options as well as the hope of a future possible targeted therapy for the underlying mechanisms of nocturnal polyuria. Biographies: Peter K Sand, MD, is Clinical Professor of Obstetrics and Gynecology at...

Epidemiology of Nocturia - Interview with Alan Wein

Details
(Length of Discussion: 12 min) Roger Dmochowski, MD and Alan Wein, MD discuss the epidemiology of nocturia, population dynamics, symptoms conditions, and how it impacts quality of life of populations across the globe. The pathophysiology, co-morbidities and challenges faced with nocturnal polyuria are also discussed. Biographies: Alan J. Wein, MD, PhD (Hon.) Roger R. Dmochowski, MD, MMHC, Program...

The RADICAL PC Project - Jehonathan Pinthus

Details
(Length of Presentation: 20 min) Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one yea...

First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small

Details
(Length of Presentation: 23 min) The first presentation of a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), called SPARTAN is provided here. Eric Small presents the SPARTAN trial first data analysis including the background, methods, primary end points, time to metastasis, progress...

Geriatric Assessment of Men with Prostate Cancer - Alicia Morgans

Details
(Length of Presentation: 16 min) Alicia Morgans, MD presents a Geriatric Assessment of Men with Prostate Cancer. She outlines the importance of geriatric considerations in prostate cancer and implementing it into the clinical management of patients. She details initial treatment decision making including staging the aging and estimation of remaining life expectancy. She also discusses consideratio...

New Concepts in ADT- Thomas Keane

Details
(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...

Advances in Bladder Cancer - Systemic Therapies Including Immunotherapy - Petros Grivas

Details
(Length of Discussion: 30 min) Petros Grivas and Alicia Morgans discuss the progress in systemic and immunotherapy in advanced bladder cancer. They discuss the biologic and immunologic background of urothelial cancer that paves the way for the development of potential biomarkers, as well as possible therapeutic targets in this disease. They share insights on the significant advances in systemic th...

Sleep Hygiene and Nocturia - Jeffrey Weiss

Details
Jeffrey Weiss discusses the importance of sleep hygiene with Diane Newman and the relationship between disordered sleep and nocturia. They highlight the standard number of hours of sleep a night for quality of life as well as the relationship of sleep cycles and nocturia. Jeffrey fields Diane's questions on dietary irritants that can lead to impaired sleeping, the importance of voiding diaries and...